



Insurer and patient costs for repeat breast surgery after initial lumpectomy for breast cancer

DAVINCI

Sam E. Wing, PhD, MPH¹; Yuki Liu, MS¹; Feibi Zheng, MD^{1,2}; Jesse Selber, MD, MPH³

¹Intuitive Surgical, Sunnyvale, CA, USA; ¹Baylor College of Medicine, Houston, TX, USA; ³Corewell Health, East, Royal Oak, MI, USA

BACKGROUND

~20-25% of patients who undergo a primary
lumpectomy for the treatment of breast cancer require a
reoperation due to adverse outcomes like positive surgical
margins or cancer recurrence

OBJECTIVE

- To analyze the **economic impact of patients who require** repeat breast tissue resection as part of their treatment.
- Describe the uptake of intraoperative risk mitigation techniques (e.g. tumor localization, frozen section pathology review) and their association with avoidance of repeat procedures

RESULTS

- 25% of patients required an additional beast surgery after their index lumpectomy, which far outpaces the society-recommended 10% threshold
- Lower age and smoking, but not high BMI, were associated with increased risk of reoperation
- Median time to second procedure was 3 weeks (IQR: 1.3-7.7 weeks)

METHODS

Study Design

- Merative MarketScan Research Database®
- Patients diagnosed with breast cancer, undergoing an index lumpectomy w/at least 3 years of continuous insurance enrollment (n = 9,433)
- Jan 2016 Dec 2021

Outcomes

- Reoperation rates (i.e. subsequent lumpectomy or mastectomy)
- Rates of intraoperative risk mitigation techniques (e.g. localization or frozen sections) within 30 days before the procedure
- All healthcare costs & out-of-pocket costs

Analysis

- Comparison Groups: Patients receiving one, definitive lumpectomy vs those requiring more than one surgery
- Comparison Time: 1-year post-index lumpectomy


CONCLUSION

- Intraoperative radiology/pathology utilization was more
 prevalent in the definitive lumpectomy group compared
 to the group requiring more than one breast resection (22.2%
 vs 20.9%, Chi Square p value = 0.009)
- Improved patient risk stratification and increased uptake
 of intraoperative adjuncts are needed to minimize risk of
 reoperation and the associated excess costs

FIGURES


Patient Pathway

Figure 1. Repeat procedure volumes




S

Figure 2. 1-Year Costs by Repeat Procedure by Procedure County



Utilization

Figure 3. Utilization of Risk Mitigation Techniques



Reoperation

Figure 4. Risk Mitigation Technique Utilization by Total Number of Breast Procedures

